Can brain scans and eye movements predict psychosis recovery?
NCT ID NCT06740383
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at 320 people with early psychosis to see if brain scans, eye-tracking, and electrical brain waves can predict how well they respond to treatment. Participants will have four visits over a year, including interviews, memory tests, and optional DNA samples. The goal is to match different biological types with the best treatments for better outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 320 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2023
- Expected to finish
-
Jun 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Participants are recruited from 5 different sites across the United States including Boston, Dallas, Hartford, Chicago, and Georgia. The target population for this study includes individuals who meet DSM-5 criteria for a psychotic disorder (i.e., schizophrenia, schizophreniform, schizoaffective disorder, bipolar I disorder or major depression with psychotic features, delusional disorder, or psychosis N.O.S.). Participants will be between 18 and 40 years of age, males and females, of all races and ethnicities who are experiencing early course psychosis.
- Ages
-
18 to 40 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Males and females, all races and ethnicities * 18-40 y/o * Meet DSM-5 criteria for a psychotic disorder, i.e. schizophrenia, schizophreniform, schizoaffective disorder, or bipolar I disorder or major depression with psychotic features, delusional disorder or psychosis N.O.S. * Able to read, speak, and understand English * Able and willing to provide written informed consent, and willing to commit to the study protocol * Illness duration from psychosis onset less than or equal to 4 years * At baseline only: receiving both psychopharmacology and psychotherapy Exclusion Criteria: * Estimated premorbid intellectual ability \<70 (WRAT-4, Word Reading subtest, age-corrected standardized score) * Neurological or medical disorder that may affect brain function (seizure disorder, traumatic brain injury with a loss of consciousness greater than or equal to 30 min, history of stroke, AIDS, etc.) * Psychoses secondary to substance use i.e., Comorbid DSM-5 diagnosis of alcohol or substance use disorders that may explain the diagnosis of psychotic disorders (individuals with cannabis use disorders unrelated to psychosis onset will be allowed. Participants encouraged to abstain from substances for 24 hours prior to lab visits) MRI-Specific Exclusion Criteria: * Pregnant women * Presence of ferromagnetic objects in body * Weight or body size exceeding scanner capacity (\>300 lbs) * Claustrophobia
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bipolar 1 disorder are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
6 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Beth Israel Deaconess Medical Center
RECRUITINGBoston, Massachusetts, 02215-5400, United States
-
Hartford Hospital
RECRUITINGHartford, Connecticut, 06102, United States
-
McLean Hospital
RECRUITINGBelmont, Massachusetts, 02478, United States
-
University of Chicago Medical Center
RECRUITINGChicago, Illinois, 60637, United States
-
University of Georgia
RECRUITINGAthens, Georgia, 30602, United States
-
University of Texas Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists probe brain's reward system in mental illness
- New schizophrenia drug targets brain glutamate, not dopamine
- New drug candidate takes aim at schizophrenia symptoms
- New schizophrenia drug goes Head-to-Head with standard antipsychotics in Long-Term trial
- Five-Year safety check for experimental schizophrenia drug
- A shot every few weeks? new drug tested for schizophrenia